Delfi Diagnostics

Baltimore, United States Founded: 2019 • Age: 7 yrs
Provider of DNA sequencing for cancer detection
Request Access

About Delfi Diagnostics

Delfi Diagnostics is a company based in Baltimore (United States) founded in 2019.. Delfi Diagnostics has raised $331.59 million across 6 funding rounds from investors including Lilly, Brown Advisory and TD Securities. Delfi Diagnostics offers products and services including DELFI Method and CASCADE-LUNG Trial. Delfi Diagnostics operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.

  • Headquarter Baltimore, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Delfi Diagnostics, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $331.59 M (USD)

    in 6 rounds

  • Latest Funding Round
    $34.33 M (USD), Debt – Conventional

    Dec 01, 2025

  • Investors
    Lilly

    & 18 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Delfi Diagnostics

Delfi Diagnostics offers a comprehensive portfolio of products and services, including DELFI Method and CASCADE-LUNG Trial. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Analyzes cell-free DNA fragments for early cancer screening.

Evaluates fragmentomics technology for lung cancer detection.

People of Delfi Diagnostics
Headcount 50-200
Employee Profiles 90
Board Members and Advisors 13
Employee Profiles
People
Kathryn Todd
Senior Director, Systems Engineering
People
Aakanksha Rangnekar
Staff Bioinformatics Engineer
People
Rob Scharpf
Head of Computational Biology & Co-Founder
People
Bridget Tripp
Senior Bioinformatics Scientist

Unlock access to complete

Board Members and Advisors
people
Greg Yap
Board Member

Unlock access to complete

Funding Insights of Delfi Diagnostics

Delfi Diagnostics has successfully raised a total of $331.59M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $34.33 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round Debt – Conventional — $34.3M
  • First Round

    (18 Jun 2018)

  • Investors Count 19
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2025 Amount Debt – Conventional - Delfi Diagnostics Valuation

investors

Jun, 2024 Amount Series B - Delfi Diagnostics Valuation Merck Global Health Innovation Fund
Jul, 2022 Amount Series B - Delfi Diagnostics Valuation DFJ Growth
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Delfi Diagnostics

Delfi Diagnostics has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Brown Advisory and TD Securities. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are directed toward innovative technology startups by DFJ Growth.
Founded Year Domain Location
No specific business activity is described for this entity.
Founded Year Domain Location
PTX Capital is involved in capital investment activities.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Delfi Diagnostics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Delfi Diagnostics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Delfi Diagnostics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Delfi Diagnostics

Delfi Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Circulating tumor DNA is screened for early cancer detection.
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Health risks are identified through online genetic and diagnostic testing.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Delfi Diagnostics

When was Delfi Diagnostics founded?

Delfi Diagnostics was founded in 2019.

Where is Delfi Diagnostics located?

Delfi Diagnostics is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.

Who is the current CEO of Delfi Diagnostics?

Susan Tousi is the current CEO of Delfi Diagnostics.

Is Delfi Diagnostics a funded company?

Delfi Diagnostics is a funded company, having raised a total of $331.59M across 6 funding rounds to date. The company's 1st funding round was a Series B of $225M, raised on Jun 18, 2018.

What does Delfi Diagnostics do?

Delfi Diagnostics was founded in 2019 and is based in Baltimore, United States. Operations focus on the biotechnology sector, where a platform employing artificial intelligence and whole genome sequencing is utilized to identify DNA fragmentation patterns in patient blood samples. Services are centered on early cancer detection through non-invasive liquid biopsy methods, supporting diagnostic applications in oncology.

Who are the top competitors of Delfi Diagnostics?

Delfi Diagnostics's top competitors include Guardant Health, GRAIL and Foundation Medicine.

What products or services does Delfi Diagnostics offer?

Delfi Diagnostics offers DELFI Method and CASCADE-LUNG Trial.

Who are Delfi Diagnostics's investors?

Delfi Diagnostics has 19 investors. Key investors include Lilly, Brown Advisory, TD Securities, Orbimed, and DFJ Growth.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available